MEMPHIS, Tenn.--()--Transnetyx, a molecular diagnostics company, announced it has processed its five millionth sample, marking a significant milestone for the company and further strengthening its foothold as a leader in the molecular diagnostics field. The sample was submitted by Jill Crittenden, Ph.D., who conducts research in the laboratory of Professor Ann Graybiel at the Massachusetts Institute of Technology (MIT).
“I’ve worked with Transnetyx for more than seven years and have found their level of service to be very helpful in accomplishing MIT’s research goals”
“We’re privileged to share this exciting milestone with all of our customers, whose research efforts made it possible,” said Bob Bean, president of Transnetyx. “As we celebrate this occasion, we’re excited by the opportunities that lie ahead for our company and look forward to many more years of providing the fastest, most accurate and cost-effective testing services to researchers and labs around the world.”
Since releasing its innovative system in 2004, Transnetyx has served the needs of biotech and medical researchers by providing automated genetic testing with a 99.998% accuracy rate. In addition to MIT, the company works with 65 other research organizations and thousands of labs around the world.
“I’ve worked with Transnetyx for more than seven years and have found their level of service to be very helpful in accomplishing MIT’s research goals,” said Crittenden.
This achievement comes on the heels of some exciting business developments for Transnetyx. Along with expanding its clientele base in mouse genotyping, the company launched Harmonyx Diagnostics in 2010 to address the high growth segment of human testing for specific pharmacogenomic applications. Harmonyx’s automated system runs a progression of diagnostic tests to help ensure a doctor’s prescription is safe and effective, and the patient receives the appropriate dosage and medication based on his or her unique genetic make-up.
Over the years, Transnetyx has also been recognized numerous times for its workplace culture and staff, including the company’s 2009 designation as Small Business of the Year by the Memphis Business Journal and MBQ: Inside Memphis Business’ selection of Bean as CEO of the Year earlier this year.
“We’re proud to have Transnetyx as part of Memphis’ robust science community,” said Dr. Steve J. Bares, President and Executive Director of Memphis Bioworks Foundation. “This milestone is a clear indication that the work that Bob and his team are doing in Memphis is truly significant in research efforts across the globe.”
Founded in 2000, Memphis-based Transnetyx is a molecular diagnostics company dedicated to serving research and saving time by removing redundant yet necessary tests conducted in genetics. Transnetyx serves biotech and medical researchers working with transgenic, knock-out/knock-in, transgenic with knock-out, or targeted mutagenesis mouse lines. For more information, visit www.transnetyx.com.